急性呼吸窘迫综合征
中性粒细胞胞外陷阱
CXCL2型
免疫系统
肺
医学
信号转导
CXCL1型
免疫学
脂多糖
内科学
炎症
细胞生物学
生物
趋化因子
趋化因子受体
作者
Meng-En Zhou,Yiman Liu,Honglin Qin,Tao Shang,Zhifeng Xue,Shuang Yang,Han Zhang,Jian Yang
标识
DOI:10.1016/j.biopha.2023.114530
摘要
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening symptoms in Coronavirus Disease 2019 (COVID-19) patients. Xuanfei Baidu Decoction (XFBD) is a recommend first-line traditional Chinese medicine (TCM) formula therapeutic strategy for COVID-19 patients. Prior studies demonstrated the pharmacological roles and mechanisms of XFBD and its derived effective components against inflammation and infections through multiple model systems, which provided the biological explanations for its clinical use. Our previous work revealed that XFBD inhibited macrophages and neutrophils infiltration via PD-1/IL17A signaling pathway. However, the subsequent biological processes are not well elucidated. Here, we proposed a hypothesis that XFBD can regulate the neutrophils-mediated immune responses, including neutrophil extracellular traps (NETs) formation and the generation of platelet-neutrophil aggregates (PNAs) after XFBD administration in lipopolysaccharide (LPS)-induced ALI mice. The mechanism behind it was also firstly explained, that is XFBD regulated NETs formation via CXCL2/CXCR2 axis. Altogether, our findings demonstrated the sequential immune responses of XFBD after inhibiting neutrophils infiltration, as well as shedding light on exploiting the therapy of XFBD targeting neutrophils to ameliorate ALI during the clinical course.
科研通智能强力驱动
Strongly Powered by AbleSci AI